AAAAAA

   
Results: 1-7 |
Results: 7
DISCONTINUATION OF MYCOPHENOLATE MOFETIL TREATMENT 6 MONTHS AFTER KIDNEY-TRANSPLANTATION
Authors: VANGELDER T YZERMANS JNM RISCHENVOS J WEIMAR W
Citation: T. Vangelder et al., DISCONTINUATION OF MYCOPHENOLATE MOFETIL TREATMENT 6 MONTHS AFTER KIDNEY-TRANSPLANTATION, Kidney international, 52(2), 1997, pp. 562-562
SUCCESSFUL MANAGEMENT OF HEMOLYSIS IN ABO-NONIDENTICAL ORTHOTOPIC LIVER-TRANSPLANTATION BY STEROID-THERAPY - A CASE-REPORT
Authors: AUWERDA JJA BAC DJ VANTVEER MB DERAVE S YZERMANS JNM
Citation: Jja. Auwerda et al., SUCCESSFUL MANAGEMENT OF HEMOLYSIS IN ABO-NONIDENTICAL ORTHOTOPIC LIVER-TRANSPLANTATION BY STEROID-THERAPY - A CASE-REPORT, Transplant international, 9(5), 1996, pp. 509-512
LONG-TERM FOLLOW-UP AFTER INDUCTION TREATMENT WITH MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) IN KIDNEY ALLOGRAFT RECIPIENTS -A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: VANGELDER T ZIETSE R YZERMANS JNM RISCHENVOS J VAESSEN LMB WEIMAR W
Citation: T. Vangelder et al., LONG-TERM FOLLOW-UP AFTER INDUCTION TREATMENT WITH MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) IN KIDNEY ALLOGRAFT RECIPIENTS -A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, Transplantation proceedings, 28(6), 1996, pp. 3221-3222
PHARMACODYNAMICS OF PROPHYLACTIC ANTIREJECTION THERAPY WITH AN ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODY (BT563) AFTER HEART AND KIDNEY-TRANSPLANTATION
Authors: HESSE CJ VANGELDER T VAESSEN LMB KNOOP CJ BALK AHMM YZERMANS JNM JUTTE NHPM WEIMAR W
Citation: Cj. Hesse et al., PHARMACODYNAMICS OF PROPHYLACTIC ANTIREJECTION THERAPY WITH AN ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODY (BT563) AFTER HEART AND KIDNEY-TRANSPLANTATION, Immunopharmacology, 30(3), 1995, pp. 237-246
MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) PREVENTS EARLY REJECTION AFTER KIDNEY-TRANSPLANTATION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: VANGELDER T ZIETSE R YZERMANS JNM VAESSEN LMB MULDER AH WEIMAR W
Citation: T. Vangelder et al., MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) PREVENTS EARLY REJECTION AFTER KIDNEY-TRANSPLANTATION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, Kidney international, 47(2), 1995, pp. 708-708
PERIPHERAL-BLOOD MONITORING DURING AND AFTER REJECTION-PROPHYLAXIS WITH A MONOCLONAL ANTI-INTERLEUKIN-2-RECEPTOR ANTIBODY IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS
Authors: VANGELDER T KNOOP CJ HESSE CJ VAESSEN LMB BALK AHMM YZERMANS JNM WEIMAR W
Citation: T. Vangelder et al., PERIPHERAL-BLOOD MONITORING DURING AND AFTER REJECTION-PROPHYLAXIS WITH A MONOCLONAL ANTI-INTERLEUKIN-2-RECEPTOR ANTIBODY IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS, Transplantation proceedings, 27(1), 1995, pp. 856-858
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY-TRANSPLANTATION
Authors: VANGELDER T ZIETSE R MULDER AH YZERMANS JNM HESSE CJ VAESSEN LMB WEIMAR W
Citation: T. Vangelder et al., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY-TRANSPLANTATION, Transplantation, 60(3), 1995, pp. 248-252
Risultati: 1-7 |